AstraZeneca’s Breztri Shows Phase III Success, Faces £115 Sell Rating
Hedge funds consider AstraZeneca one of the top immunotherapy stocks while Deutsche Bank reiterated its sell rating with a £115 target on February 16. Phase III KALOS and LOGOS showed Breztri Aerosphere delivered significant improvements over Symbicort and PT009 and cut severe asthma exacerbation rates with no new safety signals.
1. Deutsche Bank Sell Rating and Price Target
On February 16, Deutsche Bank reiterated its sell rating on AstraZeneca shares and set a price target of £115, reflecting caution despite positive clinical momentum in immunotherapy.
2. Phase III KALOS and LOGOS Trial Outcomes
Full data from the KALOS and LOGOS trials demonstrated that Breztri Aerosphere produced statistically significant lung function improvements compared with dual-combination medicines Symbicort and PT009.
3. Exacerbation Rate Reductions and Safety
Pooled analysis of KALOS and LOGOS revealed Breztri lowered annualised severe asthma exacerbation rates in patients with or without recent exacerbations, with no new safety or tolerability concerns.